's () James Barder talks to Proactive London after a 'very busy year', with three landmark steps for erectile dysfunction gel MED3000.
Firstly, Barder expects the final certificate of European CE mark approval for the medical device by the end of May as well as steps to finalise an OTC label in the US, which it aims to achieve in 2022.
Plus, securing partnering for the development and commercialisation of MED3000 in China and South East Asia. Barder says all of this is 'a real platform for the next two years, where I think we can really deliver some really exciting results for shareholders'.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...
FOR OUR FULL DISCLAIMER CLICK HERE